

Michael L Jackson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3515834/publications.pdf>

Version: 2024-02-01

89
papers

5,908
citations

94269

37
h-index

79541

73
g-index

95
all docs

95
docs citations

95
times ranked

6190
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence of bias in estimates of influenza vaccine effectiveness in seniors. <i>International Journal of Epidemiology</i> , 2006, 35, 337-344.	0.9	427
2	The test-negative design for estimating influenza vaccine effectiveness. <i>Vaccine</i> , 2013, 31, 2165-2168.	1.7	406
3	The Burden of Community-Acquired Pneumonia in Seniors: Results of a Population-Based Study. <i>Clinical Infectious Diseases</i> , 2004, 39, 1642-1650.	2.9	394
4	Influenza Vaccine Effectiveness in the 2011-2012 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on Estimates. <i>Clinical Infectious Diseases</i> , 2014, 58, 319-327.	2.9	303
5	Influenza Vaccine Effectiveness in the United States During 2012-2013: Variable Protection by Age and Virus Type. <i>Journal of Infectious Diseases</i> , 2015, 211, 1529-1540.	1.9	245
6	Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season. <i>New England Journal of Medicine</i> , 2017, 377, 534-543.	13.9	240
7	2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. <i>Clinical Infectious Diseases</i> , 2016, 63, 1564-1573.	2.9	229
8	Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season. <i>Clinical Infectious Diseases</i> , 2019, 69, 1845-1853.	2.9	218
9	Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. <i>BMJ</i> , The, 2020, 369, m1923.	3.0	166
10	Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. <i>Lancet</i> , The, 2008, 372, 398-405.	6.3	159
11	Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. <i>Journal of Infectious Diseases</i> , 2016, 213, 1546-1556.	1.9	159
12	Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season. <i>Journal of Infectious Diseases</i> , 2020, 221, 8-15.	1.9	150
13	Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 180-185.	9.0	146
14	Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. <i>Vaccine</i> , 2008, 26, 4947-4954.	1.7	144
15	Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. <i>Lancet</i> , The, 2021, 397, 398-408.	6.3	144
16	Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. <i>Morbidity and Mortality Weekly Report</i> , 2015, 64, 10-5.	9.0	144
17	Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016. <i>Clinical Infectious Diseases</i> , 2019, 68, 1444-1453.	2.9	126
18	Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. <i>Journal of Infectious Diseases</i> , 2016, 214, 1010-1019.	1.9	101

#	ARTICLE	IF	CITATIONS
19	Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1581.	3.8	91
20	Interim Estimates of 2016â€“17 Seasonal Influenza Vaccine Effectiveness â€” United States, February 2017. <i>Morbidity and Mortality Weekly Report</i> , 2017, 66, 167-171.	9.0	90
21	Influenza Vaccine Effectiveness in the United States During the 2016â€“2017 Season. <i>Clinical Infectious Diseases</i> , 2019, 68, 1798-1806.	2.9	90
22	Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. <i>Obstetrics and Gynecology</i> , 2015, 126, 1069-1074.	1.2	86
23	Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. <i>Pediatrics</i> , 2016, 137, e20153279.	1.0	80
24	Interim Estimates of 2018â€“19 Seasonal Influenza Vaccine Effectiveness â€” United States, February 2019. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 135-139.	9.0	75
25	Risk Factors for Communityâ€“Acquired Pneumonia in Immunocompetent Seniors. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 882-888.	1.3	66
26	Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness. <i>Vaccine</i> , 2015, 33, 1313-1316.	1.7	65
27	Characteristics of COVID-19 in Homeless Shelters. <i>Annals of Internal Medicine</i> , 2021, 174, 42-49.	2.0	62
28	Incidence of Herpes Zoster Among Children: 2003â€“2014. <i>Pediatrics</i> , 2019, 144, .	1.0	60
29	Classification and Regression Tree (CART) analysis to predict influenza in primary care patients. <i>BMC Infectious Diseases</i> , 2016, 16, 503.	1.3	57
30	The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries. <i>Health Affairs</i> , 2018, 37, 316-324.	2.5	57
31	Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries. <i>ELife</i> , 2021, 10, .	2.8	54
32	Postlicensure Evaluation of COVID-19 Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1939.	3.8	53
33	Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 137-42.	9.0	53
34	Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. <i>Vaccine</i> , 2018, 36, 1272-1278.	1.7	52
35	Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. <i>ELife</i> , 2021, 10, .	2.8	50
36	Association Between Estimated Cumulative Vaccine Antigen Exposure Through the First 23 Months of Life and Nonâ€“Vaccine-Targeted Infections From 24 Through 47 Months of Age. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 906.	3.8	43

#	ARTICLE	IF	CITATIONS
37	Influence of Birth Cohort on Effectiveness of 2015–2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. <i>Journal of Infectious Diseases</i> , 2018, 218, 189-196.	1.9	43
38	First Trimester Influenza Vaccination and Risks for Major Structural Birth Defects in Offspring. <i>Journal of Pediatrics</i> , 2017, 187, 234-239.e4.	0.9	42
39	Further Evidence for Bias in Observational Studies of Influenza Vaccine Effectiveness: The 2009 Influenza A(H1N1) Pandemic. <i>American Journal of Epidemiology</i> , 2013, 178, 1327-1336.	1.6	37
40	Identifying Optimal Vaccination Strategies for Serogroup A <i>Neisseria meningitidis</i> Conjugate Vaccine in the African Meningitis Belt. <i>PLoS ONE</i> , 2013, 8, e63605.	1.1	36
41	White Paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink. <i>Vaccine</i> , 2016, 34, A1-A29.	1.7	35
42	Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011–2012 and 2012–2013. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 299-308.	1.1	34
43	The impact of selection bias on vaccine effectiveness estimates from test-negative studies. <i>Vaccine</i> , 2018, 36, 751-757.	1.7	32
44	Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012–2013. <i>Clinical Infectious Diseases</i> , 2016, 62, civ952.	2.9	30
45	Can routinely collected laboratory and health administrative data be used to assess influenza vaccine effectiveness? Assessing the validity of the Flu and Other Respiratory Viruses Research (FOREVER) Cohort. <i>Vaccine</i> , 2019, 37, 4392-4400.	1.7	28
46	Burden of medically attended influenza infection and cases averted by vaccination – United States, 2013/14 through 2015/16 influenza seasons. <i>Vaccine</i> , 2018, 36, 467-472.	1.7	25
47	The Seattle Flu Study: a multiarm community-based prospective study protocol for assessing influenza prevalence, transmission and genomic epidemiology. <i>BMJ Open</i> , 2020, 10, e037295.	0.8	25
48	Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems. <i>Vaccine</i> , 2022, 40, 752-756.	1.7	23
49	Evaluating Washington State’s Immunization Information System as a Research Tool. <i>Academic Pediatrics</i> , 2014, 14, 71-76.	1.0	22
50	Vaccines and changes in coagulation parameters in adults on chronic warfarin therapy: a cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 790-796.	0.9	21
51	Confounding by Season in Ecologic Studies of Seasonal Exposures and Outcomes: Examples From Estimates of Mortality Due to Influenza. <i>Annals of Epidemiology</i> , 2009, 19, 681-691.	0.9	21
52	Cumulative and episodic vaccine aluminum exposure in a population-based cohort of young children. <i>Vaccine</i> , 2015, 33, 6736-6744.	1.7	21
53	Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 – King County, Washington. <i>Vaccine</i> , 2022, 40, 122-132.	1.7	19
54	Decreasing median age of COVID-19 cases in the United States—Changing epidemiology or changing surveillance?. <i>PLoS ONE</i> , 2020, 15, e0240783.	1.1	17

#	ARTICLE	IF	CITATIONS
55	Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012â€“2016. <i>Vaccine</i> , 2018, 36, 8047-8053.	1.7	16
56	Assessing misclassification of vaccination status: Implications for studies of the safety of the childhood immunization schedule. <i>Vaccine</i> , 2017, 35, 1873-1878.	1.7	15
57	Modeling Insights into <i>Haemophilus influenzae</i> Type b Disease, Transmission, and Vaccine Programs. <i>Emerging Infectious Diseases</i> , 2012, 18, 13-20.	2.0	14
58	Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons. <i>Vaccine</i> , 2015, 33, 5181-5187.	1.7	14
59	Effects of weather-related social distancing on city-scale transmission of respiratory viruses: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 335.	1.3	14
60	Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011â€“2012 through 2018â€“2019. <i>Vaccine</i> , 2021, 39, 1788-1796.	1.7	13
61	<i>Haemophilus influenzae</i> Type b Disease and Vaccine Booster Dose Deferral, United States, 1998-2009. <i>Pediatrics</i> , 2012, 130, 414-420.	1.0	12
62	Validation sampling can reduce bias in health care database studies: an illustration using influenza vaccination effectiveness. <i>Journal of Clinical Epidemiology</i> , 2013, 66, S110-S121.	2.4	11
63	Assessing Potential Confounding and Misclassification Bias When Studying the Safety of the Childhood Immunization Schedule. <i>Academic Pediatrics</i> , 2018, 18, 754-762.	1.0	11
64	Low-impact social distancing interventions to mitigate local epidemics of SARS-CoV-2. <i>Microbes and Infection</i> , 2020, 22, 611-616.	1.0	11
65	Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine. <i>Vaccine</i> , 2020, 38, 5880-5884.	1.7	11
66	Why do covariates defined by International Classification of Diseases codes fail to remove confounding in pharmacoepidemiologic studies among seniors?. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 858-865.	0.9	10
67	Predicting 2â€“Year Risk of Developing Pneumonia in Older Adults without Dementia. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1439-1447.	1.3	10
68	Use of self-reported vaccination status can bias vaccine effectiveness estimates from test-negative studies. <i>Vaccine: X</i> , 2019, 1, 100003.	0.9	10
69	Epidemiology of Respiratory Syncytial Virus Across Five Influenza Seasons Among Adults and Children One Year of Age and Olderâ€“Washington State, 2011/2012â€“2015/2016. <i>Journal of Infectious Diseases</i> , 2021, 223, 147-156.	1.9	10
70	Estimating Vaccine Effectiveness Against Hospitalized Influenza During Pregnancy: Multicountry Protocol for a Retrospective Cohort Study. <i>JMIR Research Protocols</i> , 2019, 8, e11333.	0.5	10
71	Estimated rates of influenzaâ€“associated outpatient visits during 2001â€“2010 in 6 <i>US</i> integrated healthcare delivery organizations. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 122-131.	1.5	9
72	Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011â€“2017. <i>Clinical Infectious Diseases</i> , 2019, 68, 1616-1622.	2.9	9

#	ARTICLE	IF	CITATIONS
73	Temporal Trends in Undervaccination: A Population-Based Cohort Study. <i>American Journal of Preventive Medicine</i> , 2021, 61, 64-72.	1.6	9
74	RE: "INVITED COMMENTARY: BEWARE THE TEST-NEGATIVE DESIGN". <i>American Journal of Epidemiology</i> , 2017, 185, 613-613.	1.6	8
75	Incidence of Medically Attended Acute Respiratory Illnesses Due to Respiratory Viruses Across the Life Course During the 2018/19 Influenza Season. <i>Clinical Infectious Diseases</i> , 2021, 73, 802-807.	2.9	8
76	Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 921-925.	0.9	7
77	Reducing Antibiotic Use in Ambulatory Care Through Influenza Vaccination. <i>Clinical Infectious Diseases</i> , 2020, 71, e726-e734.	2.9	7
78	Challenges in comparing the safety of different vaccination schedules. <i>Vaccine</i> , 2013, 31, 2126-2129.	1.7	6
79	Initial validation of a simulation model for estimating the impact of serogroup A <i>Neisseria meningitidis</i> vaccination in the African meningitis belt. <i>PLoS ONE</i> , 2018, 13, e0206117.	1.1	6
80	Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011-2016. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 380-390.	1.5	5
81	Vaccine effectiveness against COVID-19 among symptomatic persons aged 12 years with reported contact with COVID-19 cases, February-September 2021. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 673-679.	1.5	4
82	Order of Live and Inactivated Vaccines and Risk of Non-vaccine-targeted Infections in US Children 11-23 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 247-253.	1.1	3
83	Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged 16 Years in the United States, February-May 2021. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	3
84	Patterns of childhood immunization and all-cause mortality. <i>Vaccine</i> , 2017, 35, 6643-6648.	1.7	2
85	Reply to Skowronski, De Serres, and Orenstein. <i>Clinical Infectious Diseases</i> , 2019, 69, 1085-1086.	2.9	2
86	Differences between Frequentist and Bayesian inference in routine surveillance for influenza vaccine effectiveness: a test-negative case-control study. <i>BMC Public Health</i> , 2021, 21, 516.	1.2	2
87	Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States. <i>Vaccine</i> , 2021, 39, 3324-3328.	1.7	2
88	Influenza vaccine effectiveness in elderly people. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1169-1170.	4.6	1
89	Reply to: Quality Indicators of Drug Use and Risk of Pneumonia in Older Adults without Dementia. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1365-1366.	1.3	0